

PATENT APPLICATION UPDATE

Acrux (ASX: ACR) today provided an update on the examination by the US Patent and Trademark Office (USPTO) of Acrux's underarm administration patent application. This patent was granted in Australia in September 2011 and notice of allowance has been received in New Zealand. Applications are under examination in a number of other countries around the world.

The examination process in the US has included a series of submissions by Acrux and responses from the USPTO. Today Acrux received a response to its latest submission from the USPTO, in which the examiner has raised objections to the patent claims. Acrux remains confident in the merits of the patent claims and intends to continue the examination process.

Contact

Richard Treagus, CEO: 0417 520 509

About Acrux

- Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.
- Fast-drying, invisible sprays or liquids provide a delivery platform with low or no skin irritation, superior cosmetic acceptability and simple, accurate and flexible dosing. The technology platform is covered by broad and well-differentiated, issued patents.
- Acrux has products marketed by licensees in the USA, approved in Europe, Canada and Australia and in registration or development.